Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Yuan, J.
  • Mehta, P. P.
  • Yin, M. J.
  • Sun, S. X.
  • Zou, A. H.
  • Chen, J.
  • Rafidi, K.
  • Feng, Z.
  • Nickel, J.
  • Engebretsen, J.
  • Hallin, J.
  • Blasina, A.
  • Zhang, E.
  • Nguyen, L.
  • Sun, M. H.
  • Vogt, Peter K.
  • McHarg, A.
  • Cheng, H. M.
  • Christensen, J. G.
  • Kan, J. L. C.
  • Bagrodia, S.

publication date

  • November 2011

journal

  • Molecular Cancer Therapeutics  Journal

abstract

  • Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently in human cancer and contributes to resistance to antitumor therapies. Inhibition of key signaling proteins in the pathway therefore represents a valuable targeting strategy for diverse cancers. PF-04691502 is an ATP-competitive PI3K/mTOR dual inhibitor, which potently inhibited recombinant class I PI3K and mTOR in biochemical assays and suppressed transformation of avian fibroblasts mediated by wild-type PI3K γ, δ, or mutant PI3Kα. In PIK3CA-mutant and PTEN-deleted cancer cell lines, PF-04691502 reduced phosphorylation of AKT T308 and AKT S473 (IC(50) of 7.5-47 nmol/L and 3.8-20 nmol/L, respectively) and inhibited cell proliferation (IC(50) of 179-313 nmol/L). PF-04691502 inhibited mTORC1 activity in cells as measured by PI3K-independent nutrient stimulated assay, with an IC(50) of 32 nmol/L and inhibited the activation of PI3K and mTOR downstream effectors including AKT, FKHRL1, PRAS40, p70S6K, 4EBP1, and S6RP. Short-term exposure to PF-04691502 predominantly inhibited PI3K, whereas mTOR inhibition persisted for 24 to 48 hours. PF-04691502 induced cell cycle G(1) arrest, concomitant with upregulation of p27 Kip1 and reduction of Rb. Antitumor activity was observed in U87 (PTEN null), SKOV3 (PIK3CA mutation), and gefitinib- and erlotinib-resistant non-small cell lung carcinoma xenografts. In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity. PF-04691502 has entered phase I clinical trials.

subject areas

  • Adenosine Triphosphate
  • Animals
  • Antineoplastic Agents
  • Binding, Competitive
  • Cell Cycle Checkpoints
  • Cell Line, Tumor
  • Enzyme Inhibitors
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Neoplasms
  • Phosphatidylinositol 3-Kinases
  • Protein Binding
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidines
  • Signal Transduction
  • TOR Serine-Threonine Kinases
  • Xenograft Model Antitumor Assays
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1535-7163

Digital Object Identifier (DOI)

  • 10.1158/1535-7163.mct-11-0185

PubMed ID

  • 21750219
scroll to property group menus

Additional Document Info

start page

  • 2189

end page

  • 2199

volume

  • 10

issue

  • 11

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support